Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071102 | 0.89 | CYP4F2 (0.45) | SMN1; SMN2MAPK1MEN1KMT2ACYP4F2 | |
| SCHEMBL29210884 | 0.86 | CYP4F2 (0.46) | SMN1; SMN2MAPK1MEN1KMT2ACYP4F2 | |
| SCHEMBL1659167 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1MEN1KMT2ACYP4F2 | |
| SCHEMBL11345271 | 0.85 | CYP4F2 (0.49) | MAPK1MEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL2289682 | 0.83 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPK1MEN1KMT2APOLB | |
| SCHEMBL24242177 | 0.83 | TSHR (0.41) | MAPK1MEN1KMT2APOLBMAPT | |
| SCHEMBL13269452 | 0.83 | OPRM1 (0.49) | MAPK1MEN1KMT2APOLBMAPT | |
| SCHEMBL21399965 | 0.83 | CYP4F2 (0.47) | MAPK1MEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL6060809 | 0.82 | CYP4F2 (0.50) | SMN1; SMN2MAPK1MEN1KMT2ACYP4F2 | |
| SCHEMBL22098179 | 0.82 | CYP4F2 (0.63) | SMN1; SMN2MAPK1MEN1KMT2ACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932420-B2 | Lowering intraocular pressure; glaucoma | ALLERGAN, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932420-B2 | Lowering intraocular pressure; glaucoma | ALLERGAN, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080167331-A1 | Novel sulfonamides | BURK ROBERT M | 2008-07-10 | — | — | US | disclosed |
| US-20080167331-A1 | Novel sulfonamides | BURK ROBERT M | 2008-07-10 | — | — | US | disclosed |
| EP-1919862-A2 | NOVEL SULFONAMIDES | ALLERGAN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7314890-B2 | Sulfonamides | ALLERGAN, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314890-B2 | Sulfonamides | ALLERGAN, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| WO-2007024611-A2 | SULFONAMIDES OF 7 -AMINOHEPTANOIC ACID DERIVATIVES FOR TREATING GLAUCOMA | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070043090-A1 | Novel Sulfonamides | ALLERGAN, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070043090-A1 | Novel Sulfonamides | ALLERGAN, INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167331-A1 | Novel sulfonamides | NR2E3, NR5A2, HRH4 | SMN1; SMN2 993/4885MAPK1 3665/4885MEN1 1714/4885 |
| US-20070043090-A1 | Novel Sulfonamides | NR2E3, NR5A2, HRH4 | SMN1; SMN2 993/4885MAPK1 3665/4885MEN1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.